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ABSTRACT 
 
Source Characterization and Pretreatment Evaluation of Pharmaceuticals and Personal 
Care Products in Healthcare Facility Wastewater. (May 2011) 
Pranav Mukund Nagarnaik, B.Tech., Nagpur University;  
M.S., Syracuse University 
Chair of Advisory Committee: Dr. Bryan Boulanger 
 
Healthcare facility wastewaters are a potentially important and under 
characterized source of pharmaceuticals and personal care products in the environment.  
In this study, the composition and magnitude of pharmaceuticals and personal care 
products (PPCPs) released into a single municipality‟s wastewater system from a 
hospital, a nursing care facility, an assisted living facility and an independent living 
facility are presented for 54 pharmaceuticals, 8 hormones and 31 Alkylphenol 
ethoxylates (APEOs).  Chemical oxidation using molecular ozone and advanced 
oxidation processes (AOPs) (UV-hydrogen peroxide, Fenton‟s Reagent, and Photo – 
Fenton‟s Reagent) were screened and evaluated as potential treatment technologies for 
removal of APEOs in water and wastewater.   
In this research, APEOs were found to be the dominant PPCP class out of 94 
individual analytes measured, accounting for more than 65% of the total mass loading 
observed leaving the healthcare facility wastewater.  Seventy one out of the total 
measured PPCPs were detected in wastewater from at least one of the facilities.  
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Healthcare facilities‟ wastewater is the source of PPCPs in the environment; however, 
their contribution to the total magnitude of PPCPs in municipal wastewater and the 
surrounding environment will be determined by the relative flow contribution of 
wastewater released from the facility to the municipal sewer network.  Molecular ozone 
and advanced oxidation processes were observed to remove APEOs from analyzed water 
matrices; however, understanding the product formation during the oxidation process is 
important before concluding a suitable treatment process.  Molecular ozone reacted 
selectively with the double bond in the APEO, while AOPs reaction was non selective 
oxidation.  During the AOPs, OH· formation rate and scavenging rate constant in 
wastewater was found to be the factor governing the oxidation process.  Thus, the 
research carried out informs risk management decisions concerning the prevalence of 
PPCPs in the wastewater, and the use of oxidation systems as treatment technologies for 
removal of PPCPs.   
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1. INTRODUCTION TO DISSERTATION RESEARCH 
1.1 Overview of Environmental Pharmaceuticals and Personal Care Products 
(PPCPs) 
1.1.1 Prevalence  
PPCPs are gathering increased attention as environmental contaminants due to 
their presence in wastewater effluents and potable water supplies.  Because 
pharmaceuticals and many personal care products are intended to illicit a biological 
response by design, their presence in environmental and potable waters is of concern. 
Kolpin et al. first raised awareness of the widespread presence of PPCPs in 
environmental waters in 2000 when they reported the findings of their United States 
Geological Survey (USGS) national surface water quality survey [1].  The goal of their 
survey was to develop analytical methodologies needed to perform a screening level 
occurrence assessment of PPCPs in environmental waters and to determine 
concentrations of PPCPs in the aquatic environments.  The results of the Kolpin et al. 
survey identified 80 PPCPs in 111 US waterways.   
The Kolpin et al. dataset was followed up by a Focazio et al. study who 
performed another screening level occurrence assessment of PPCPs in source waters 
used for drinking water treatment using the same methodology and design from the 
previous USGS survey[2]. 
__________________ 
This dissertation follows the style of Environmental Science and Technology. 
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The source water survey results indicated the widespread presence of PPCPs in 
potable source water supplies with 63 PPCPs reported in at least one of 74 municipal 
source waters above parts per billion levels.  
While the Kolpin and Focazio et al. studies continue to be the most prominent 
works to date concerning PPCPs as environmental contaminants, the presence of 
individual PPCPs in wastewater has been reported since the early 1970s.  
Pharmaceuticals, antibiotics[1, 3-7], anticonvulsants [2, 8-12], anti-anxiety[1, 2, 
13],anti-inflammatory [8, 9, 11, 13-19],  anti-psychological[20, 21], cardiovascular 
drugs[1, 11, 14, 21], hormones [22-30] and respiratory pharmaceuticals [1, 21, 31] have 
all been reported in surface water and wastewater effluents.  Natural hormones, 
including estrogens [30, 32-37], androgens [38-41], and progestogens [22, 24, 29, 37, 
39, 42] are also widely reported in the environment and wastewater effluents.  
1.1.2 Risk of PPCPs as environmental contaminants  
While occurrence data has demonstrated the widespread nature of PPCPs in 
environmental waters and treated effluents, far less is understood concerning the 
ecological risk of exposure to PPCPs in the environment. Because these organic 
compounds are designed to be biologically active, a certain risk can be anticipated for 
organisms exposed to environmental PPCPs even when the concentrations of PPCPs in 
the environment are low.  For instance, several PPCPs are known to be endocrine 
disrupting chemicals (EDCs).  The most widely studied PPCPs that are known to behave 
as EDCs at environmentally relevant concentrations are natural and synthetic hormones 
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[43-45] and alkylphenols (APs), which are degradation products of alkyphenol 
ethoxylates (APEOs) widely used in detergents.   
Hormones, including prescription hormones, have demonstrated biological 
receptor impacts below 5 parts-per-trillion [28].  Their presence in treated effluents 
leaving wastewater treatment systems contribute to the adverse physiological effects 
noted in fish downstream from wastewater effluent discharges [30, 46-48].  The 
estrogenicity of APs is also established, with octyl- or nonyl- phenol being the most 
estrogenic.  While APs are far less potent than hormones in their effect on the estrogen 
receptor of exposed organisms, AP concentrations in wastewaters are normally three 
orders of magnitude higher than hormone concentrations.  Therefore, the relationship 
between a compound‟s potency and concentration is important to consider.  In addition 
to hormones and alkylphenols, many other PPCPs are assumed to be EDCs, however, 
their direct ecological impacts at environmentally relevant concentrations are disputed.   
The risk to humans from exposure to PPCPs (including the EDCs mentioned in 
the past paragraph) in environmental waters is more disputed than the ecological risks of 
PPCP exposure.  Although the presence of pharmaceuticals at the parts-per-trillion levels 
in the drinking water does not currently appear to pose a direct adverse risk to humans, 
indirect impacts from some pharmaceuticals are documented and need to be considered.  
For instance, Guardabassi et al. demonstrated that discharges containing hospital 
wastewater increased the prevalence of oxytetracycline-resistant isolates among 385 
strains of Acinetobacter in monitored environmental systems [49].  Reinthaler et al.  
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showed similar impacts of hospital wastewaters on multiple antibiotic resistance of 767 
isolates of E. coli in samples wastewater treatment plants [50].   
Hartmann et al. have also reported that fluoroquinolone antibiotics have shown 
mutagenic and carcinogenic genotoxicity at environmentally relevant concentrations 
[51].  While the exact mechanisms of transferring antibiotic resistance due to the 
influence of hospital wastewater is an area of current research, it is known that antibiotic 
resistant genes can also be transferred horizontally by conjugation through cell-to-cell 
contact or by transformation when resistant plasmid DNA is transferred into bacteria 
[52].  Therefore, indirect impacts, such as development of antibiotic resistant bacteria, 
must be considered while assessing potential risk of environmental pharmaceuticals.  
Indirect impacts of other PPCPs on human health are more difficult to determine.  
Limited toxicology studies of chronic exposures exist to assess low level, long term 
exposures to anticonvulsants, antidepressants, antihypertensives, or cytostatics 
pharmaceuticals in the most utilized animal-humans models.  Their presence in the 
potable water supply is, therefore, a highly controversial and debated topic. 
1.1.3 Healthcare facilities as sources of PPCPs to municipal wastewater   
Contamination of environmental waters with PPCPS is widespread and our 
understanding of associated exposure risks is limited.  As a precautionary measure, risk 
management efforts to characterize sources of PPCPs to environmental systems and 
promote removal of PPCPs from known release points are needed.  Source 
characterization data for important societal sources of PPCPs that contribute to 
municipal wastewater loadings is lacking.  Use data of PPCPs is also difficult to obtain 
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across sectors of society or on an individual community/household basis.  However, the 
healthcare sector controls the flow of prescription pharmaceuticals to patients and 
administers doses at much higher levels than are usually prescribed to the general public. 
Healthcare facilities also administer hormone therapy using natural and synthetic 
hormones.  These facilities also are consumers of detergents used in house to launder 
linens.  Therefore, healthcare facilities are a logical starting point when attempting to 
characterize important social sources of PPCPs released to municipal wastewater 
treatment systems.      
In the United States there are approximately 9,178 general medical and surgical 
hospitals (North American Industry Classification System (NAICS) Code: 622110), 
21,459 nursing care facilities (NAICS Code: 623110), 6,843 continuing care retirement 
communities (NAICS Code: 623311) and 3,491 homes for elderly (NAICS Code: 
623312) providing healthcare services to millions of patients [53].  The importance of 
these healthcare facilities as a potential point source contributor of PPCPs to municipal 
wastewater systems is widely anticipated, but there is a lack of information in the 
literature regarding the concentration and magnitude of PPCPs in the wastewater from 
these facilities.    
Starting in the mid 1980s, researchers began developing methods to determine 
the concentration of individual pharmaceutical classes in hospital effluents that were 
released either due to patient excretions or disposal practices of expired pharmaceuticals.  
Kummerer et al. investigated chemotherapeutic platinum-based compounds, which was 
the first class of pharmaceutical compounds investigated.  Platinum-based 
  
6 
pharmaceuticals were detected in the wastewater from one hospital within a 
concentration range  of 10 – 610 ng/L platinum [54].  Later Mahnik et al. furthered the 
earlier work of Kummerer et al. when they reported the presence of antineoplastic agents 
for cancer treatment (non-platinum based drugs) in the wastewater effluents of a hospital 
[55-58].  Mahnik et al. reported a concentration level ranging from 8.6 – 124 g/l for 
doxorubicin, eprubicin and daunorubicin [59].   
Following the work of Herberer and Mahnik, Brown et al. evaluated the presence 
of eleven antibiotics in effluents from a hospital, residential area, dairy and a wastewater 
treatment plant[59].  Antibiotic concentrations for ofloxacin, trimethoprim and 
sulfamethaxazole in hospital wastewater were reported to be 36, 2.9, and 2.1 µg/L, 
respectively [3].  Gomez et al. expanded the list of known pharmaceuticals in hospital 
wastewaters by reporting the presence of codine (analgesic), atenolol (cardiovascular), 
ranitidine (gastroenterological), metronidazole (antibiotic) and ketorolac (analgesic) in 
the wastewater from a small hospital with concentrations of the individual analytes 
ranging from 0.06 – 151 g/L [16, 60].   
While determining the concentration of pharmaceuticals in hospital effluents is 
timely, concentration data alone does not allow for the characterization of hospital 
effluents as sources of pharmaceuticals to the environment.  In order to characterize 
hospitals as a source, flow data needs to be integrated to determine a mass loading of 
pharmaceuticals from these facilities.  Heberer et al. were the first group to undertake a 
mass loading calculation.  In 2005 they published a report exploring the concentration 
and mass loading of carbamazepine (an antiepileptic) in wastewater from a military 
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hospital.  Their findings indicate a total mass loading of carbamazepine leaving the 
hospital to be 4 – 460 grams per week [61].  
From the limited source characterization data available in the literature, it is 
apparent that hospitals do release some pharmaceuticals to municipal sewer systems.  
However, hospital effluents have not been evaluated for the presence of many of the 
most commonly prescribed pharmaceuticals or for other personal care products.  
Additionally, while the presence of PPCPs in other types of healthcare facilities is 
anticipated, the PPCP concentration and magnitude in other types of healthcare 
providing facilities is not previously reported.   
1.1.4 Pretreatment of healthcare facility wastewaters as a risk management approach 
 Because of the anticipated occurrence of PPCPs in healthcare facility 
wastewaters it is important to consider the available options that exist for 
implementation of PPCP pretreatment technologies at identified sources.  Pretreatment 
options of interest include physical, chemical, and microbial based treatment processes.  
However, due to the risk of developing antibiotic resistant bacteria, microbial based 
treatment technologies should be considered as a last-resort option. 
  Physical-chemical treatment processes such as nano-filtration, reverse osmosis, 
oxidation and advanced oxidation demonstrate proven potential to separate or oxidize 
organic contaminants in aqueous systems [62, 63].  For pretreatment on-site, however, 
advanced oxidation has greater promise due to its smaller space requirement and lower 
initial cost.  Because of the scalability and cost of advance oxidation processes, there has 
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been a steady increase in the number of articles appearing in the literature regarding the 
evaluation of different AOPs for removal of PPCPs over the past decade.   
Despite the growing literature, only one study to date reports on the effectiveness 
of an advanced oxidation technology to degrade a PPCP (ciprofloxacin) using real 
hospital effluent samples as the test matrix.  In their study, ciprofloxcin with an initial 
concentration of 200 µg/L was completely destroyed within 1 hr using a heterogeneous 
photocatalytic process [64].  The remainder of related literature is full of reports of 
AOPs that have been evaluated based upon spiking PPCPs into distilled water or 
drinking water samples [64].  In all cases, only a limited amount of analytes were 
evaluated at a time.  In order to understand the actual effectiveness of existing oxidation 
technologies, evaluations should be done with real samples to evaluate matrix 
competition for the oxidants.   
1.2 Research Plan 
After a collective evaluation of the literature, this project was planned to develop 
source characterization data for PPCPs in healthcare facility wastewaters and to evaluate 
the performance of oxidation technologies to remove a selected class of PPCPs from 
water and wastewater.  The following two hypotheses were defined to guide this risk 
management based research: 
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1.2.1 Hypothesis 1:  Healthcare facilities are a source of PPCPs to municipal 
wastewaters.   
Wastewaters from four different healthcare facilities (including a hospital, an 
assisted living facility, an independent living facility, and a nursing home) within the 
same municipality were evaluated for 54 pharmaceutical analytes, 29 APEOs, two APs, 
and nine hormone analytes.  The importance of hypothesis 1 was to motivate work to 
obtain a comprehensive dataset that can be used to characterize healthcare facilities as a 
source of PPCPs to municipal sewer systems.  Also, the majority of these analytes have 
never been reported in healthcare facility effluents prior to this dissertation research.   
1.2.2 Hypothesis 2: Chemical oxidation processes can be used to remove APEOs from 
water and wastewater. 
Chemical oxidation systems that use molecular ozone and/or the hydroxide 
radical were screened and evaluated as potential treatment technologies for removal of 
APEOs in water and wastewater.  APEOs were selected for further study because this 
class of personal care products is commonly used in commercial detergents and 
demonstrates endocrine disrupting properties at environmentally relevant concentrations.  
APEOs were also identified at the high concentrations within the healthcare facility 
effluents evaluated by research motivated by Hypothesis 1 and their removal using 
oxidation technologies has not been previously reported.   
The removal of APEOs using ozone, Fenton‟s reagent, ozone-hydrogen peroxide, 
and UV-hydrogen peroxide was evaluated in laboratory water in order to determine the 
reaction kinetics, stoichiometry, and product identification in order to clarify the reaction 
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mechanism.  The oxidation technologies were also evaluated for their ability to remove 
APEOs in water and wastewater collected from the field  to explore the effect of the 
matrix on kinetics.  Samples were collected from tap water, hospital effluent, wastewater 
treatment plant influent, and wastewater treatment plant effluent.  Collectively, these 
oxidation process evaluations inform risk management decisions concerning the use of 
oxidation systems as pre-treatment technologies for source reduction of PPCPs at 
healthcare facilities or other sources of PPCPs to municipal wastewaters.  
1.3 Organization of this Dissertation 
This dissertation has been organized as a collection of six papers collected 
together and presented in individual sections.  Section 1 presents an overview of 
environmental PPCPs, provides the research plan, and explains the organization of the 
dissertation.  Section 2 summarizes each of the four papers on source characterization of 
healthcare facilities completed to evaluate Hypothesis 1.  Three of the four papers are 
published in peer-reviewed journals and the fourth paper is currently submitted and 
undergoing the peer review process.  Section 2 provides an overview of these four 
papers and presents additional statistical analysis of the data that is not found within the 
published/submitted papers. 
Section 3 presents a submitted paper currently in peer-review at Chemosphere 
concerning the reaction of APEOs with hydroxide radicals generated through different 
advanced oxidation techniques.  Section 4 presents a submitted paper concerning the 
reaction of APEOs with molecular ozone also in review at Chemosphere.  Both papers 
include an exploration of reaction kinetics, stoichiometry, and metabolism identification 
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to clarify the reaction mechanism of APEOs with oxidation systems potentially used for 
pretreatment purposes. Both papers present research carried out in laboratory and field 
waters (aqueous environmental matrices) that also explore the impact on the matrix on 
removal of APEOs from the sample. 
The dissertation concludes with Section 5, where conclusions from the study and 
suggestions for possible future directions of research are presented along with a few 
lessons learned and parting thoughts. 
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2. SCREENING LEVEL ASSESSMENT OF HEALTHCARE FACILITIES AS 
SOURCES OF PPCPS TO MUNICIPAL WASTEWATERS 
2.1 Introduction 
While the presence of these pharmaceuticals and EDCs in the environment is 
established, sources of these compounds to the environment are less well characterized.  
Healthcare facilities are a potentially important source of EDCs and pharmaceuticals to 
the environment that are particularly under characterized.  
The primary aim of this section is to detail research concerning our hypothesis 
that all healthcare facilities, including but not limited to hospitals, are sources of PPCPs 
to the municipal wastewater systems. This section provides a summary of four papers 
that assess the concentrations and magnitude of environmental loadings of nine natural 
and synthetic steroid hormones, 29 APEOs, two APs, and 54 pharmaceuticals from four 
different healthcare facilities. These papers include:   
 Nagarnaik, P.M., M.A. Mills, and B. Boulanger, Concentrations and mass 
loadings of hormones, alkylphenols, and alkylphenol ethoxylates in healthcare 
facility wastewaters. Chemosphere, 2010. 78(8): p. 1056-1062. 
 Nagarnaik, P., A. Batt, and B. Boulanger, Concentrations and mass loadings of 
cardiovascular pharmaceuticals in healthcare facility wastewaters. Journal of 
Environmental Monitoring, 2010. 12(11): p. 2112-2119. 
 Nagarnaik, P., A. Batt, and B. Boulanger, Source characterization of nervous 
system active pharmaceutical ingredients in healthcare facility wastewaters. 
Journal of Environmental Management, 2011. 92(3): p. 872-877 and 
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 Nagarnaik, P., A. Batt, and B. Boulanger, Healthcare facility effluents as a point 
source of selected pharmaceuticals to municipal wastewater. Water Environment 
Research, Sumitted. 
Collectively, these four papers provide an estimation of daily mass loadings 
contributed by a multi specialty hospital, multi care skilled nursing facility, an assisted 
living facility, and an independent living facility located within a single municipality in 
Texas.  The papers were split up for publication based upon the peer-review process 
feedback and the methods used to measure each of the respective analyte classes across 
three United States Environmental Protection Agency (US EPA) laboratories.  This 
section provides a summarized report of the findings in order to provide insight on the 
relative contributions and magnitudes of analyzed PPCPs released to municipal 
wastewater systems from healthcare facilities monitored within this dissertation 
research.  
2.2 Experimental 
Experimental details are provided within each paper, but are summarized in brief 
below [65-67].  A description of the four different healthcare facilities within a single 
municipality in Texas that were sampled during our research is provided in Table 2-1.  
Please note that all facility names are withheld to protect the location identities.  Twenty-
four hour composite samples of each facility‟s wastewater effluent were collected and 
analyzed using an ISCO autosampler.  The ISCO sampler collected 100 ml of 
wastewater every 15 mins for 24 h and stored it in an ice-chilled 10-L polypropylene 
bottle.  The collected samples from each facility were then sub-sampled using a 
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peristaltic pump into 1 L pretreated amber glass bottles in the field and shipped to the 
corresponding EPA laboratories for analysis.  
Table 2-1 Description for each healthcare facility sampled in this study 
Facility 
Name 
NAICS Name 
 and Code 
# of 
Beds 
Wastewater 
 Flowrate 
Description of Services 
Hospital 
General medical 
and surgical 
hospital, 622110 
375 
500,000 
L/day 
in patient general hospital 
care, coronary care, surgical, 
and intensive care; 
outpatient cardiac, 
orthopedic, obstetrics and 
gynecology, pulmonary, 
surgical, gastrointestinal and 
respiratory care 
Nursing 
Care 
Nursing care 
facility; 623110 
300 
100,000 
L/day 
nursing care, physical 
rehabilitation, Alzheimer‟s 
care, and hospice 
Assisted 
Living 
Continuing care 
retirement 
communities, 
623311 
225 
50,000 
L/day 
custodial non-medical care, 
as well as personalized 
medical care including 
medication management 
services, Alzheimer‟s care, 
and short-term skilled 
nursing care 
Independent 
Living 
Homes for elderly 
(NAICS:623312) 
225 
70,000 
L/day 
short-term custodial non-
medical care services and 
limited healthcare services 
in the area of onsite therapy, 
wellness, and rehabilitation 
providers 
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2.2.1 Analytical methods 
Four different analytical techniques were used for the analysis of steroid 
hormones, long-chain APEOs, short-chain APEOs, APs and pharamceuticals.  Table 2-2 
and Table 2-3 provide a summary of all individual analytes measured in this study.  All 
analyses were performed using laboratory standard operating procedures developed in 
accordance with EPA‟s quality assurance program.  All analytical data presented in this 
study was corrected to account for matrix effects based upon the matrix spike recovery 
controls present within each independent method. 
All hormone samples were extracted and analyzed according to US EPA‟s 
National Risk Management Research Laboratory‟s (NRMRL) “Standard Operating 
Procedure (SOP) for the Analysis of Steroid Hormones in Aqueous Samples (Revision 
4r)”. This SOP details the extraction and analysis of eight hormones: 17-estradiol, 
estrone, estriol, 17-ethynylestradiol, testosterone, androstenedione, progesterone, and 
dihydro-testosterone.  The SOP used to analyze the hormones is similar to the procedure 
previously reported by Esperazna et al. [29].  The acceptable surrogate recovery was 
between 60 and 140%.  All long-chain APEO samples were analyzed using US EPA‟s 
Region 5 Central Research Laboratory‟s SOP MS006 V1 (“Laboratory for analysis of 
nonylphenol polyethoxylates (NPnEO, 3 ≤ n ≤ 18) and octylphenol polyethoxylates 
(OPnEO, 2 ≤ n ≤ 12) in wastewater samples using selected ion recording liquid 
chromatography / mass spectrometry (LC/MS)”).  The detailed description of the 
method is provided elsewhere [65-67].  The acceptable range of matrix spike recovery 
was defined to be between 60 and 140%.  All AP and short-chain APEOs were analyzed 
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using ASTM D7065-06 (“Standard Test Method for Determination of Nonylphenol, 
Bisphenol A, p-tert-Octylphenol, Nonylphenol Monoethoxylate and Nonylphenol 
Diethoxylate in Environmental Waters by Gas Chromatography Mass Spectrometry”) 
[68].    The acceptable range of matrix spike recovery was defined to be between 60 and 
140%. 
Table 2-2 Pharmaceuticals measured in this study grouped by the Anatomical 
Therapeutic Chemical (ATC) classification system 
ATC Code A: Alimentary tract and metabolism 
Cimetidine A02BA01 
Ranitidine A02BA02 
Glyburide A10BB01 
Glipizide A10BB07 
ATC Code B: Blood and blood forming organs 
Warfarin B01AA03 
ATC Code C: Cardiovascular system 
Clonidine C02AC01 
Hydrochlorothiazide C03AA03 
Furosemide C03CA01 
Triamterene C03DB02 
Fluocinonide C05AA11 
Propranolol C07AA05 
Metoprolol C07AB02 
Atenolol C07AB03 
Amlodipine C08CA01 
Verapamil C08DA01 
Norverapamil* C08DA01 
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Table 2 – 2 continued 
ATC Code C: Cardiovascular system 
Diltiazem C08DB01 
Desmethyldiltiazem* C08DB01 
Enalapril C09AA02 
Valsartan C09CA03 
Simvastatin C10AA01 
Atorvastatin C10AA05 
Gemfibrozil C10AB04 
ATC Code G: Genito-urinary system and sex 
hormones 
Norethindrone G03AC01 
Testosterone G03BA03 
Progesterone G03DA04 
ATC Code H: Systemic hormonal preparations, 
excluding insulins 
Betamethasone H02AB01 
Methylprednisolone H02AB04 
Prednisolone H02AB06 
Prednisone H02AB07 
Hydrocortisone H02AB09 
ATC Code J: Antiinfectives for systemic use 
Trimethoprim J01EA01 
Sulfamethoxazole J01EC01 
ATC Code M: Musculo-skeletal system 
Ibuprofen M01AE01 
2-hydroxy-ibuprofen* M01AE01 
ATC Code N: Nervous system 
Oxycodone N02AA05 
Propoxyphene N02AC04 
Acetaminophen N02BE01 
Carbamazepine N03AF01 
Benzatropine N04AC01 
Alprazolam N05BA12 
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Table 2 – 2 continued 
ATC Code N: Nervous system 
Amitriptyline N06AA09 
10-hydroxy-amitriptyline* N06AA09 
Fluoxetine N06AB03 
Norfluoxetine* N06AB03 
Paroxetine N06AB05 
Sertraline N06AB06 
Desmethylsertraline* N06AB06 
Amphetamine N06BA01 
ATC Code R: Respiratory system 
Albuterol R03AC02 
Fluticasone R03BA05 
Theophylline R03DA04 
Hydrocodone R05DA03 
Promethazine R06AD02 
* compounds are metabolites.  For the metabolites the 
same ATC code as the parent compound is listed. 
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Table 2-3 Hormones and APs/APEOs measured in this study 
Hormones APs/APnEOs* 
Androgens Octylphenol Nonylphenol 
Androstenedione OP2EO NP3EO 
Dihydrotestosterone OP3EO NP4EO 
Testosterone OP4EO NP5EO 
Estrogens OP5EO NP6EO 
Estriol OP6EO NP7EO 
Estrone OP7EO NP8EO 
17 -ethynylestradiol OP8EO NP9EO 
17 -estradiol OP9EO NP10EO 
Progestagens OP10EO NP11EO 
Progesterone OP11EO NP12EO 
 OP12EO 
 
NP13EO 
  NP14EO 
  NP15EO 
  NP16EO 
  NP17EO 
  NP18EO 
 
* APnEO represents an alkyl phenol ethoxylate with an ethoxylate chain length of n  
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Specific details of the pharmaceutical preparation, extraction, and analysis are 
presented elsewhere [65, 67, 69].  Pharmaceutical samples were extracted with 150 mg 
Oasis HLB MCX cartridges® and were analyzed using a Waters Aquity ultra 
performance liquid chromatography coupled to a Micromass Quattro Micro triple 
quadrupole mass spectrometer.  The acceptable target recoveries were set between 60% 
and 140%.  For presentation purposes, pharmaceuticals were classified based upon the 
first level of the Anatomical Therapeutic Chemical (ATC) classification system. This 
classification system is used to group pharmaceuticals based upon their target organ or 
system.  Analyte classification became necessary in order to interpret data and facilitate 
discussion.   
The analyzed pharmaceuticals were distributed across 9 of the 14 therapeutic 
categories within the ATC system as given in Table 2-2.   
2.2.2 Mass loading 
The average daily and monthly flow rates from each facility were obtained from 
the municipality where the samples were acquired.  The total mass loading from each 
facility was calculated by multiplying individual analyte concentrations in the composite 
sample from each facility composite by the average daily flow for that facility.  The 
estimated mass loadings are reported as ng/day for the hormone analytes and 
pharmaceuticals and g/day for the APEO analytes.   
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2.2.3 Statistical analyses 
Matlab™ was used to organize analyte concentration data by site and to perform 
the statistical analysis.  The data was first checked for normality using the Shapiro-Wilk 
test and then checked for equality of variance using Lavene‟s test.  The data was found 
to be non-normal and unequal in variance and a non-parametric analysis was used to 
interpret the statistical relationships between composites.  For non-parametric analysis, a 
post hoc two-way Friedman‟s ranks test was performed first, followed by step-wise 
multiple comparisons tests.  The non-parametric method used in the data analysis was 
selected to control for a potential increase of the type I error caused by multiple 
comparison testing.  Only analytes that were present in at least one of the four 
composites were included in the statistical analysis.  Analytes that were present at one 
site and nondetectable at another had their non-detect concentration set to zero in order 
to perform the statistical analysis.     
Cluster analysis (CA) was performed in order to further understand the relative 
similarities between the sites.  The multivariate cluster analysis classifies and groups the 
objects based on the similarities within the system.  Hierarchical clustering forms the 
clusters in a sequential manner with a decreasing similarity of subgroups merged into a 
single cluster.  CA was applied to wastewater from all healthcare facility and PPCP 
concentrations using a single linkage method.  Each analyte concentration is considered 
as a data point and the minimum distance between two sites is calculated by: 
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                                               2-1
Where          is the Euclidean distance, xi and xj are the concentrations for 
each analyte at the paired sites, and A and B are the pair of sites.  At each step the 
distance is found for every pair of the clusters and the two clusters with smallest distance 
are merged.  After two clusters are merged the procedure is repeated for the next step.  
The result of a hierarchical clustering procedure can be displayed graphically using a 
tree diagram, also known as a dendrogram, which shows all the steps in the hierarchical 
procedure and the resulting relationships between PPCP concentrations between sites. 
2.3 Summary of Source Characterization Papers’ Results and Discussions 
2.3.1 PPCP composition in healthcare effluents 
Table 2-4 represents the frequency of detection of analytes within the four 
healthcare facility wastewater composite samples broken down and grouped into 
pharmaceutical, hormone, and AP/APEO analytes. The hospital had the highest 
measured occurrence of all the analytes, followed by the independent living facility, the 
nursing facility, and the assisted living facility.   
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Table 2-4 Frequency of detection at four healthcare facilities wastewaters 
Facility 
# 
Pharmaceutical 
# 
Hormones 
# 
APs/APEOs 
# Total 
Hospital 37/54 7/9 22/31 
66/94 
Nursing Facility 36/54 7/9 13/31 
56/94 
Assisted Living 22/54 4/9 16/31 
42/94 
Independent Living 38/54 5/9 15/31 
58/94 
 
The mean concentration and relative standard deviation of PPCPs analyzed in 
four healthcare facility wastewaters can be found for each analyte within the individual 
papers [65-67].  In summary forty-one out of the 54 measured pharmaceutical analytes 
were detected in at least one site.  Out of the total targeted 54 pharmaceuticals, 39% 
were detected in all four sampled sites.  Analyte percent recovery in the matrix spike 
recovery (MSR) samples varied by analyte in each sample matrix.  Matrix spike 
recovery was within the acceptable target range (60% - 140%) for 73% of all analytes, 
less than 60% for 11% of all analytes, above 140% for 6.5 % of all analytes, and unable 
to be determined due to the high magnitude of the analyte present in the sample for 4% 
of the analytes. The analyte with the maximum mean concentration for each ATC 
classified code group was ranitidine (0.9 g/L) for ATC Code A; warfarin (0.07 g/L) 
for B; valsartan (14.6 g/L) for C; hydrocortisone (0.4 g/L) for J; ibuprofen (30 g/L) 
for M; amitriptyline (0.3 g/L) for N; and hydrocodone (0.2 g/L) for R.  Thirteen 
pharmaceutical analytes were not detected in any of the sampled facility‟s wastewaters.  
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The hospital, nursing care facility, assisted living and independent living had 7, 6, 4 and 
6 individual pharmaceutical analytes present at concentrations higher than 1 g/L. 
Seven out of the eight analyzed steroid hormones were detected in at least one of 
the facility composite samples.  Androstenedione and progesterone were found in 
wastewater from all of the healthcare facilities with a concentration range from 9 ng/L 
progesterone in the independent living facility composite to 127 ng/L androstenedione in 
the hospital‟s composite sample.  Overall, the hospital composite sample had the highest 
measured concentration of each hormone analyte, except for 17-estradiol.  The 
maximum concentration of 17-estradiol was nominally higher in the nursing care 
facility. Perhaps surprisingly, the synthetic 17-ethynylestradiol was not observed in any 
of the facility composites.   
For APs and APEOs, nonylphenol (NP) and octylphenol (OP) were not detected.  
For the monoethoyxlate and diethoxylate nonyl- and octylphenols surrogate recoveries 
did not meet QA/QC limits, therefore, they are not reported although no presence of 
these compounds was evident during analysis.   
All NPEO and OPEO chain lengths, (NPnEO, 3<n<18) and (OPnEO, 
2<n<12), respectively, were summed to give the total concentration discussed here.  The 
sum of NPEO (3<n<18) will be identified as NPEO and the sum of OPEO (2<n<12) 
will be identified as OPEO.   The concentrations of NPEO are an order of magnitude 
higher than of OPEO for the facility composites.  Overall, the assisted living facility 
composite had the highest NPEO concentrations (258 g/L), followed by the hospital 
composite (111 g/L), the independent living facility composite (26 g/L), and the 
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nursing facility composite (19 g/L).  The hospital composite had the highest 
concentration of OPEO (13 g/L) followed by multi care nursing care facility (2 g/L).  
OPEO were not detected in the assisted living or independent living facility 
composites.   
The higher incidence and magnitude of NPEO compared to OPEO in this study 
appear to be supported by production estimates.  Approximately 80% of the total APEOs 
used as surfactants are NPEOs [47, 48, 70].  The presence of all long-chain APEOs 
(n>2) and lack OP and NP is also of interest.  The high amount of long-chain APEOs 
dominating the healthcare facility wastewaters sampled in this study signifies a source 
signature as APEOs in detergents degrade to APs during the wastewater treatment 
process.  The presence of NPEOs distributed in chain lengths from eight to three may 
indicate that breakdown of the APEO chain length begins to occur at the source.     
2.3.2 PPCP mass loading estimates in healthcare effluents  
The overall mass loading of PPCPs in a facility‟s wastewater was estimated in 
order to understand the relative importance of healthcare facilities as a source of 
different groups of PPCPs.  Figure 2-1 illustrates the relative contribution of total 
pharmaceuticals, APs/APEOs and hormones within each healthcare facility wastewater 
using pie charts.  The size of the pie chart indicates the total mass loading of all 
measured PPCPs within each facility relative to each other.  Maximum mass loading of 
total PPCPs was found in effluents from the hospital (94 g/day) followed by that from 
the nursing care facility (26 g/day), assisted living facility (13 g/day) and independent 
living facility (11 g/day).   
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At the hospital, assisted living, and independent living facilities, APs/APEOs 
contributed to more than 65% of the total mass loading of PPCPs, signifying the 
importance of this compound class within healthcare facilities.  Within the nursing care 
facility, pharmaceuticals had the highest contribution followed by APs/APEOs.   
 
 
 
Figure 2-1 Relative contribution of analytes to wastewater loadings for each healthcare 
facility.  The total mass loading (g/day) observed for each facility is also presented. 
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The estimated mass loading of pharmaceuticals from each facility was 1.1 g/day 
from the assisted living facility, 2.2 g/day for independent living facility, 24 g/day from 
the nursing care facility, and 31 g/day from the hospital with a combined pharmaceutical 
mass loading from all facilities of ~58 g/day. 
Five pharmaceutical analytes could explain 80% or more of the total 
pharmaceutical loading at each location. The large contribution of five pharmaceutical 
analytes is of interest for risk management purposes and appears to follow logically from 
the type of healthcare treatment occurring at each facility.  It is of interest that the four 
highest contributors of pharmaceutical mass loading (from our analyte sets) in the 
assisted living facility and independent living facility are all cardiovascular medications, 
whereas the top five pharmaceutical contributors in the multi-care nursing facility were 
two anti-infectives and three of the measured cardiovascular medications.  The presence 
of pain medications and high amounts of anti-infectives is perhaps no surprise for a 
facility that covers many levels of healthcare from skilled nursing to hospice.  High daily 
flow from the hospital facility explains the higher magnitude of pharmaceutical released 
when the hospital is compared to the other facilities.  
The estimated total mass loading of APEOs from all facilities indicates that 
healthcare facilities may be a significant point source contributor of APEOs (and thus 
APs) to the municipal wastewater system.  The total mass loading of APEOs from all 
facilities was estimated to be 70 g/day.  The hospital contributed approximately 80% of 
the total mass loading of APEOs from all facilities with 54 g/day leaving the hospital.  
This finding highlights the importance of understanding mass loadings of analytes.  The 
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concentration of APEOs in the assisted living facility wastewater composite sample was 
more than two times higher than in the hospital wastewater composite sample.  
However, the hospital‟s daily wastewater flow (500,000 L/day) was ten times higher 
than the assisted living facility‟s flow (50,000 L/day).  In order to make risk 
management decisions, characterization data presented in the literature must include 
flow data from each source in order to determine mass loadings.   
The hormone mass loadings from the healthcare facilities are three orders of 
magnitude lower in comparison to the APEO loadings.  The estimated total mass flow of 
hormones ranged from 92 mg/day at the hospital to 2 mg/day at the assisted living 
facility.  The overall androgen contribution to the total mass loading of hormones was 
more than 65% at all the facilities, with androstenedione contributing more than 40% of 
the observed mass loading for each site.  With such a small mass loading of steroid 
hormones, it appears unlikely that healthcare facilities are a significantly elevated source 
of hormones to municipal wastewater systems.  This result is partially surprising, 
because the hospital wastewater included wastewater from a labor and delivery unit.  
However, an elevated estrogen signal was not observed.   
2.3.3 Statistical analysis  
The concentration data within each composite were determined to be non-
normally distributed for each sampled facility.  Therefore, non-parametric Friedman‟s 
methodologies were used to evaluate statistical relationships occurring between PPCPs 
concentrations from each healthcare facility wastewater.  Friedman‟s test does not treat 
the two composite sites symmetrically and it does not test for any interaction between 
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two sites, instead it is a test to evaluate the difference between each sampled facility‟s 
observed concentrations. 
The Friedman test begins by rank–ordering the measures for each analyte 
concentration.  The null hypothesis in this scenario is that the four different healthcare 
facilities‟ do not differ with respect to the concentration of analytes.  The statistical 
analysis showed that there wasn‟t a significant difference between four healthcare 
facilities‟ wastewater (p=0.1972) with respect to summed pharmaceutical 
concentrations.  However a significant difference was observed between at least one of 
the four healthcare facilities‟ wastewater for hormones (p = 0.007) and APs/APEOs (p 
<0.0001).  In order to further understand the differences within the healthcare facilities, 
multiple comparison tests were performed using the statistical information obtained from 
Friedman‟s test.  This results in a pair wise comparison of each facility.  Figure 2-2 
displays a graph for the estimates with the intervals around them.  The symbol represents 
the mean rank of each facility, while the solid line represents the 95% confidence 
interval about the mean.  In this approach two means are significantly different if their 
intervals are disjoint and not significantly different if their intervals overlap.  The 
Multiple Comparison Test reveals that there is no significant difference between all the 
healthcare facilities for pharmaceutical analytes grouped together.  For hormones, the 
assisted and independent living facility hormone concentrations were significantly 
different and lower than the hormone concentrations observed in hospital and nursing 
facility wastewater.  APEO concentrations in nursing home and independent living 
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facility wastewater were also significantly different and lower than APEOs in hospital 
and assisted living facility wastewater.  
The dendrogram obtained from hierarchical cluster analysis is presented in 
Figure 2-3.  This figure shows the relative similarities based on the concentration of 
different groups of PPCPs (pharmaceuticals, hormones and APs/APEOs) and different 
healthcare facility wastewater can be observed.  When the concentration of 
pharmaceuticals was considered, the assisted living and independent living facility 
wastewater was found to be most similar followed by the hospital and then by the 
nursing care facility.  For hormone concentrations, the cluster analysis revealed that the 
nursing care facility and the independent living facility wastewater were most similar 
followed by the assisted living facility and the hospital.  Finally for APEOs, the nursing 
care facility and independent living facility were most similar in concentration, followed 
by the hospital and the assisted living facility. Thus, from the statistical non parametric 
analysis and cluster analysis it can be observed that the similarity between different 
healthcare facility wastewater is dependent on the group of PPCP being considered.  No 
other correlation between the different healthcare facilities effluent concentration could 
be established, however, the maximum concentration within each PPCP class seemed to 
conceptually agree with the type of care services provided at each healthcare facility. 
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Figure 2-2 Frideman‟s non parametric test followed by a multiple comparison test to 
understand the difference between each healthcare facility's observed concentrations 
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Figure 2-3 Dendrogram for sampled facilities according to the observed PPCP 
concentrations 
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2.4 Summary of Source Characterization Papers’ Conclusions 
Taken as a whole, the data provided within this section and within the four 
papers provide the most comprehensive dataset currently available for evaluating risk 
management options for PPCPs originating at healthcare facilities.  The provided data 
informs risk assessment discussions by providing source characterization data for PPCPs 
not previously reported for hospital, nursing, assisted living, and independent living 
facility wastewaters.  Our research provides an initial dataset for municipal officials, 
regulators, and healthcare facility operators that can be used to identify if risk 
management approaches should be implemented to reduce the release of PPCPs from 
healthcare facilities in their jurisdiction.  
Of particular interest is the observation that the sub part-per-billion and part-per-
trillion pharmaceutical and hormone analyte concentrations observed in this study are 
within the same order of magnitude for the same analytes reported in the literature for 
wastewater influents.  This finding suggests that healthcare facilities are not significant 
sources of pharmaceuticals and hormones to municipal wastewaters when PPCPs are 
considered as a whole.  However, the intensive use of detergents (observed by high 
concentration of APEOs in the effluents) in the healthcare facilities could be an 
important source of APs to the environment when APEO based detergents enter the 
municipal system and transform to APs during conveyance and treatment.   
Additionally, the data indicate that the magnitude and importance of healthcare 
facilities as a source will vary based upon the specific PPCP of interest and the flow that 
the healthcare facility contributes to the municipal wastewater conveyance and treatment 
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system.  In the municipal wastewater conveyance system sampled as part of this 
research, the sampled healthcare facility wastewaters only made up 0.2% of the total 
wastewater flow received by the municipality‟s treatment plant.   Therefore, for risk 
management purposes, it is important to consider that the importance of healthcare 
facilities as sources of PPCPs to the municipal wastewater system will likely be most 
dependent upon the location of the facility in the network and the relative flow 
contribution of healthcare facility effluent to a municipal treatment plants total flow.    
The risk of analyzed PPCPs within the environment is still a contentious issue.  
While the risk created by environmental exposures to pharmaceuticals is not easily 
quantified, the risk associated with hormones, APs, and APEOs in wastewater can be 
assessed (by one measure) through calculation of a samples estrogenicity.  Relative 
potencies for hormones and APEO degradation products and the calculation for 
determining estrogenicity is present in the literature [66].  Based upon this metric, all of 
the wastewaters were estrogenic, with approximately 65% of the total estrogenicity 
imparted by the APEO degradation products in the samples.  While the relative potency 
of APEO degradation products are three orders of magnitude lower than 17-estradiol, 
the concentration of APEOs makes up for the difference in the relative potency.  Based 
upon our interpretation of the data, the presence of APEOs in the sampled healthcare 
facility wastewaters warrant further investigation into pretreatment measures that could 
be used to reduce the concentration of APEOs from leaving the source.    
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3. ADVANCED OXIDATION OF ALKYLPHENOL ETHOXYLATES IN 
AQUEOUS SYSTEMS 
3.1 Introduction 
Alkylphenol ethoxylates (APEOs) are non-ionic surfactants commonly used to 
formulate products such as detergents, paints, dispersing agents, wetting products, 
pesticides, and petroleum recovery chemicals [71, 72].  Their widespread use in 
industrial and commercial formulations has resulted in the increased report of APEOs as 
common environmental contaminants found in surface water [48, 73, 74], groundwater 
[75-77] and wastewater [47, 71, 72, 78-80].  APEOs are not completely biodegradable 
under normal environmental conditions and result in the formation of environmentally 
persistent and endocrine system active alkylphenols (APs) [30, 47, 81-84].  While the 
estrogenic potential of APs are 3-4 orders of magnitude lower than estradiol‟s estrogenic 
activity [83, 85-87], the concentration of APEOs and APs present in environmental 
samples is normally three to four orders of magnitude greater than the concentration of 
hormones [30, 48, 75, 78, 88].  Therefore, the estrogenic potential of a water or 
wastewater realized when APEOs breakdown to APs can be significant.  Reducing the 
presence of endocrine disrupting contaminants, such as nonylphenol and estrogens, from 
entering the environment has been a primary concern for wastewater engineers over the 
past decade.      
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Physical and chemical processes such as filtration, oxidation and advanced 
oxidation have been commonly used for the removal of endocrine disrupting 
contaminants from wastewater [77].  Removal of APs by filtration, membrane 
bioreactors, ozone, hydrogen peroxide, electrochemical processes and advanced 
oxidation techniques is reported [77, 89-92].  However, available literature exploring the 
treatment efficiency of different processes to degrade APEOs is currently limited.  
Research evaluating the degradation of APEOs is important to assess pretreatment 
options for facilities where APEOs are produced or extensively used, as a recent study 
determined that APEOs present in industrial wastewater remain practically unchanged at 
the source [93].   
Advanced oxidation processes (AOPs) produce the hydroxyl radical (OH∙), 
which is commonly used to eliminate organics from water and wastewater [94-96].  OH∙ 
is a highly reactive, non-selective oxidant with a high oxidation potential (2.86 eV) [97].  
The effectiveness of an AOP to remove oxidize organics present in a matrix depends on 
the rate of OH∙ formation and the availability of OH∙ to react with the target organic 
compound.  Effectiveness of different AOPs for oxidation of different micro 
contaminants in the environment is well documented in literature [20, 95, 96].  However, 
oxidation of APEOs using AOPs has not previously been explored to the best of our 
knowledge.  
Research was performed to explore the oxidation of APEOs by AOPs in 
ultrapure water and in aqueous environmental matrices.  Three AOPs were explored to 
determine the ability of each AOP to degrade APEOs in aqueous systems.  The AOPs 
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studied were hydrogen peroxide in the presence of ultraviolet light (UV/H2O2), Fenton‟s 
reagent (Fe/H2O2), and photo-Fenton‟s (UV/Fe/H2O2). The purpose of this research was 
to understand the reaction kinetics of APEOs in the presence of OH∙, monitor any 
observed degradation products, and to use APEO removal data within AOP systems to 
evaluate a predictive model for the removal of APEO in aqueous environmental matrices 
based upon OH∙ formation rate and OH∙ scavenging rate constant.  This predictive model 
has important implications for evaluating the effectiveness of AOPs as treatment or 
pretreatment technologies for removal of APEOs within municipal and industrial 
wastewater systems.   
3.2 Experimental Section 
3.2.1 Chemicals and reagents 
ACS grade phosphoric acid, phosphate buffer, tertiary butanol, 
parachlorobenzoic acid, HPLC grade acetonitrile and water, H2O2, ferric sulfate, and 
glacial acetic acid were purchased from Fisher Scientific (Pittsburg, PA).  Ultrapure 
water was produced in the laboratory using a Barnstead NANOpure water unit.  UV light 
was generated using a 254 nm UV lamp contained in a boxed enclosure in order to keep 
out residual light and for safety purposes.  
Triton-X 100
TM
 and Tergitol 15™ were purchased from Dow Chemical 
(Midland, MI).  Triton-X 100™ is a mixture of octylphenol ethoxylates (OPEOs) with 
an average ethoxylate chain length of 10.  Tergitol 15™ is a mixture of nonylphenol 
ethoxylates (NPEOs) with an average chain length of 15.  Spiking solutions of OPEO 
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and NPEO were prepared by diluting 20 g/L stock solutions of the two APEOs using 
ultrapure water.  The 20 g/L stock solutions were created by dissolving neat compound 
as received from Dow in ultrapure water at 40 
o
C while stirring.  Stock and spike 
solutions were immediately used upon creation.   
3.2.2 Experimental setup 
Oxidation of OPEO and NPEO was explored using three AOP systems including 
UV/H2O2 (UH), Fe/H2O2 (FH), and UV/Fe/H2O2 (UFH).  Reactions were carried out in 
triplicate within 2 L glass beakers to evaluate each process.  1 L of aqueous sample was 
placed in each beaker and spiked with either OPEO or NPEO at a concentration of 5 
M.  Reaction systems that involve UV irradiation were carried out by placing 
individual reactors within the boxed UV enclosure.  The reactors inside the enclosure 
were placed on a multiposition stir plate and the surface of the reactor solution was 12.5 
cm from the UV source.     
OH∙ reaction kinetics with the two APEOs was studied by measuring the 
degradation of OPEO and NPEO in the UH system in ultrapure water with a H2O2 
concentration of 0.6 mM.  The rate constant for the reaction of OPEO and NPEO with 
OH∙ was determined through competition kinetics with methylene blue as the reference 
compound.  The rate of OH∙ formation from each AOP and the OH∙ scavenging rate 
constant for each aqueous environmental matrix were calculated.   
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3.2.3 Analytical measurements 
Samples from the oxidation reactions in laboratory ultrapure water and four 
aqueous environmental matrices were analyzed for APEOs, dissolved organic carbon 
content (DOC), and dissolved ozone and were screened for the formation of degradation 
products.  The four aqueous environmental matrices used in this study were collected in 
10 L volumes.  The sources of the samples were potable water, a wastewater effluent 
conveyance channel, a wastewater influent main, and an effluent main from a municipal 
hospital.  All samples were collected into polypropylene bottles using a peristaltic pump 
with teflonated tubing and were immediately placed on ice and returned to the laboratory 
for testing.  Prior to their use in the semi-batch reactor system, the aqueous 
environmental matrices were filtered through a 1 m glass fiber filter.     
3.2.4 APEO analysis 
Extraction and analysis of APEOs was performed at US EPA Region 5‟s Central 
Research Laboratory (R5CRL) according to US EPA R5CRL‟s standard operating 
procedure MS006 V1.  Reaction solutions (1 L) received 3 mL of methanol and 1 mL of 
formaldehyde to preserve the samples and were shipped overnight to R5CRL in 1 L 
amber glass bottles packed on ice.   The full method is described in a previous 
publication [66].  Briefly, 1L of filtered sample (0.45 m) was analyzed using a Waters 
2659 liquid chromatography coupled with a single quadrapole ZQ mass spectrometer.  
The analytes were separated using an Atlantis ™ MS C18 column (150 mm x 2.1 mm x 3 
m).  The target analytes were quantified using a single ion recording (SIR) operated 
under atmospheric electrospray positive ion mode.  The details about the 
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instrumentation, method detection limits and quality control protocol is reported within 
the CRL‟s SOP.  A five point calibration curve was used to quantify total NPEO and 
total OPEO based upon the primary ion response for NPEOs with an ethoxylate chain 
length between 3 and 18 and OPEOs with an ethoxylate chain length between 2 and 12.  
The secondary ion response of each individual NPEO and OPEO was used for 
verification.  Analyte recovery was assessed through matrix spiked additions of OPEO 
and NPEO at a concentration of 100 ppb.  The acceptable range of recovery used in the 
analysis and reporting of experimental data was 60% to 140%. 
3.2.5  Measuring para-chlorobenzoic acid in solution   
Para-chlorobenzoic acid (p-CBA) is used in experiments to determine the ratio of 
OH∙ formation for individual AOPs and OH∙ scavenging rate constant for each matrix.  
The concentration of p-CBA in reaction solutions is measured using a UV 
spectrophotometer operated at 235 nm using a six point external calibration curve. 
3.2.6 Total organic carbon 
Total dissolved organic carbon was analyzed using a Shimadzu 6000V TOC 
Analyzer according to Standard Method 5310B [98]. 
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3.3 Results and Discussion 
3.3.1 Reaction kinetics and degradation products formed during the reaction of 
APEOs with OH∙ 
The reaction kinetics and degradation products of the reaction of APEOs with 
OH∙ were evaluated in ultrapure water using the UH system.  Because the reaction rate 
constant for the reaction of APEO with OH∙ is expected to be in the range of 107-1011 M-
1
s
-1
, the second-order rate constant determined in this research was calculated using 
competition kinetics ([99-104]).  The application of the competition kinetics model in 
our experimental system leads to the following relationship described in equation (3-1).  
   
      
       
  
        
     
   
   
    
       3-1 
where [APEO]0 and [R]0 are the initial concentration of APEO and the reference 
compound (methylene blue) at time = 0,       is the rate constant for the reference 
compound (4.1x10
9 
M
-1
s
-1
),          is the second-order rate constant for the reaction 
of APEO with OH∙, and [APEO] and [R] are the concentrations of APEO and the 
reference compound at time = t.  The slope obtained by plotting    
      
       
  versus 
   
   
    
  was used to determine the second-order rate constant.  The second-order rate 
constant for NPEO and OPEO were both determined to be 1.1x10
10
 M
-1
s
-1
. These rate 
constants are similar to the 10
7
 to 10
11 
range of second-order rate constants for the 
reaction of organics with OH∙ presented in the literature [95, 96, 101, 105]. 
Figures 3-1 and 3-2 present a time series evaluation of the reaction products that 
clearly indicates the formation of shorter chain length ethoxylates during chemical 
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reaction.  Reaction products observed in the reaction solutions that were not present in 
the initial spiked solution include OP3EO for the OPEO investigation and NP2EO, and 
NP3EO for the NPEO investigation.  Therefore, fragmentation of the ethoxylate chain 
length does occur during advanced oxidation of APEOs.    However, the overall 
concentration of all ethoxylate chain lengths decreases at each time step from an initial 
concentration of 5 M down to 0.05 M after fifteen minutes.   While a slight increase 
in the concentration of lower APEOs was observed over time, the data does not 
distinguish whether the observed lower ethoxylates formed due to progressive 
fragmentation of the ethoxylate chain length or from the non-selective attack of OH∙ at 
various parts of the molecule.       
While the fast rate of reaction between OH∙ and APEOs indicates that treatment 
of APEOs in aqueous environmental matrices using advanced oxidation processes is 
favorable, the resulting oxidation of APEOs by individual AOPs will be dependent upon 
aqueous environmental matrix used in experimental system.  
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Figure 3-1 Concentration of individual nonylphenol ethoxylates (NPEOs) measured 
during the reaction of NPEOs with hydroxyl radical in ultrapure water within the 
UV/H2O2 system after five and twelve minutes of reaction 
0.1
1
10
100
1000
[N
P
EO
] 
(m
g/
L)
Time = 0 mins
Time = 5 mins
Time = 12 mins
Generation
Increase
  
44 
 
Figure 3-2 Concentrations of individual octylphenol ethoxylates (OPEOs) measured 
during the reaction of OPEOs with hydroxyl radical in ultrapure water within the 
UV/H2O2 system after five and twelve minutes of reaction 
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3.3.2 Oxidation of APEOs in different aqueous matrices  
The impact of different aqueous environmental matrices on APEO oxidation by 
each evaluated AOP reaction system was also evaluated.  Table 3-1 shows the 
experimental conditions and the resulting APEO removal after ten minutes of reaction 
for each AOP – matrix pair.  APEO removal was greatest in tap water followed by 
wastewater effluent, wastewater influent, and hospital effluent in respective order.  This 
observation is intuitive as less oxidant is available for oxidation of the APEOs when 
higher amounts of DOC are present to scavenge OH∙.  Therefore, the difference in the 
APEO removal for each matrix-AOP pair can be explained based on the OH· formation 
rate and scavenging rate constant.    
3.3.3 Determining OH· formation rate and scavenging rate constant in matrix-AOP 
pairs  
The oxidation of an organic target compound [P] with OH∙ depends on the 
second-order rate constant of the target compound, the rate of OH∙ formation from each 
AOPs and the OH∙ scavenging rate constant of the matrix.  The rate of target compound 
oxidation in a batch reactor d[P]/dt by OH∙ follows pseudo first-order reaction kinetics 
described by Equation (3-2) [106]. 
 
 
    
  
                3-2 
where [P] is the concentration of target analyte in solution and       is the pseudo first-
order rate constant which is function of OH· formation rate and scavenging rate constant.    
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Table 3-1 Percent removal of APEOs in environmental aqueous matrices after ten 
minutes of reaction for each matrix - AOP reaction pair 
AOP Aqueous Matrix H2O2 Fe UV OPEO NPEO 
  M M  % removal %removal 
UH Ultrapure water 600 - 254 nm 97.1 97.1 
UH Tap water 600 - 254 nm 76.4 73.5 
UH WWTP effluent 600 - 254 nm 53.0 62.2 
UH WWTP influent 600 - 254 nm 14.8 8.5 
UH Hospital effluent 600 - 254 nm 11.8 3.1 
FH Ultrapure water 100 25 - 85.8 82.2 
FH Tap water 100 25 - 63.4 67.6 
FH WWTP effluent 100 25 - 26.7 27.7 
FH WWTP influent 100 25 - 5.2 8.9 
FH Hospital effluent 100 25 - 3.8 0.6 
UFH Ultrapure water 100 25 254 nm 95.5 94.4 
UFH Tap water 100 25 254 nm 60.5 63.9 
UFH WWTP effluent 100 25 254 nm 23.9 34.7 
UFH WWTP influent 100 25 254 nm 17.4 24.7 
UFH Hospital effluent 100 25 254 nm 12.5 12.1 
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Determination of  OH· formation and scavenging rate constant is accomplished 
by measuring the removal of para-chlorobenzoic acid (p-CBA, a commonly used probe 
compound) spiked into solution in the presence of tertiary butanol (t-BuOH, a known 
OH· scavenger) in each matrix-AOP pair. The initial concentration of p-CBA in solution 
is kept constant at 5 M while the initial concentrations of t-BuOH are varied from 50, 
100, 200, 600, and 1000 M in each matrix – AOP pair.  The decrease in the p-CBA 
concentration in these experiments also follows the pseudo first-order kinetics as 
described in equation 3-3.  For each matrix-AOP pair, five kexpt value are calculated from 
the slope of the concentration time profile of p-CBA for five different t-BuOH initial 
concentrations using Equation (3-3).   
    
      
       
             3-3 
Figure 3-3 shows the plot between    
      
       
  and time for the tap water–UH 
pair.        is also further defined in Equation (3-4) as: 
                     3-4 
Where          is a second-order rate constant known from literature and   is 
the ratio between OH∙ formation rate and scavenging rate constant within each matrix-
AOP pair.    is described mathematically by Equation 3-5  
  
  ·               
  ·                         
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 3-5 
The components of the OH· scavenging rate constant are known or found 
experimentally.  Under the given experimental conditions, DOC, bicarbonate/carbonate 
ion, H2O2 and tBuOH are the predominant OH∙ scavengers species present in the 
different water matrices. 
 
 
Figure 3-3 Degradation of p-CBA in tap water during the reaction with OH· and p-CBA 
within the UV/H2O2 system.  The value of kexpt is calculated for five t-BuOH 
concentrations  
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Substituting Equation (3-5) into Equation (3-4) results in Equation 3-6. 
.   
              
 
                            
                                 
        
3-6 
  Taking the inverse of Equation (3-6) and separating out terms results in 
Equation (3-7).  
 
     
 
                            
               
         
 
         
         
          3-7 
Figure 3-4 shows a linear plot of Equation (3-7) where 
 
     
 is plotted versus 
tBuOH concentration for one of the matrix–AOP pairs (tap water-UH).  The slope of this 
graph is used to calculate OH· formation rate   and the y-intercept is used to determine 
the value of        .    and         were calculated for each matrix-AOP pair using 
this methodology.  The resulting OH∙ formation rate   for a given AOP and the 
        for each matrix are presented in Table 3-2.           values presented in 
Table 3-2 are within the range of reported         values (1.4 – 8.6 x 10
4
 L mg
-1
 s
-1
) 
for different wastewater effluents reported in the literature [106, 107].   
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Figure 3-4 Plot of 1/kexpt found from equation  3-3 versus t-BuOH concentration for the 
UV/H2O2 system and all water matrices 
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Table 3-2 Hydroxyl radical formation rate () for each AOP and second-order kinetic 
constant for DOC (kOH-DOC) of each environmental water matrix used in this study with 
additional measured water quality parameters 
Water [DOC] 
[HCO3
-
 / 
CO3
2+
] 
        UH FH UFH 
 mg C/L M 
L mg
-1
 s
-1
 
(x10
-3
) 
M s
-1
 
(x10
8
) 
M s
-1 
(x10
8
) 
M s
-1
 
(x10
8
) 
Tap Water 0.71 8.92E-03 
7.14 
(±0.75) 
3.49 
(±0.18) 
1.51 
(±0.10) 
2.86 
(±0.32) 
WWTP 
Effluent 
3.54 7.67E-03 
48.41  
(±1.61) 
WWTP 
Influent 
22.14 6.83E-03 
57.31 
(±8.14) 
Hospital 
effluent 
27.38 5.58E-03 
60.69 
(±1.76) 
 
 - Hydroxyl radical formation rate, UH – UV/H2O2, FH – Fe/H2O2, UFH – Fe/UV/H2O2 
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The total scavenging rate constant for each matrix were calculated to be 1.0x10
5
 
s
-1
 for tap, 2.6x10
5
 s
-1
 for WWTP effluent, 15x10
5
 s
-1
 for WWTP influent and 17x10
5
 s
-1
 
for hospital effluent.  The OH∙ scavenging rate constant for natural water systems have 
been reported as 3x10
4
 s
-1
 for low DOC lake water to 3x10
5
 s
-1 
for secondary effluents 
following treatment [107].  The OH∙ scavenging rate constant is dependent on the 
concentration of total dissolved organic matter and the concentrations of inorganic 
scavenger compounds present in water.  This explains why the highest OH∙ scavenging 
rate constant calculated in our studies was for the hospital effluent and the WWTP 
influent.  Also, while tap water had the highest concentration of HCO3
-
/CO3
2- 
(9x10
-3
 
M), it also had the lowest concentration of dissolved organic matter (0.7 mgC L
-1
).  As a 
result the total OH∙ scavenging rate constant for tap water was lowest in comparison to 
the other aqueous environmental matrices.   
In addition to the OH∙ scavenging rate constant, the rate of OH∙ formation () 
was also calculated from the above equations.  The OH∙ formation rate did not change 
with the different water matrices, however differences in radical formation based upon 
the individual AOP was observed. 
3.3.4 APEO percent removal in matrix-AOP pairs 
Within our experimental system the extent of observed APEO removal within 
each matrix-AOP pair was dependent directly on the OH· formation rate and inversely 
dependent on OH· scavenging rate constant of the water matrix.  In order to access this 
dependency, APEO concentrations for each matrix – AOP pair were predicted after 10 
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minutes of reaction by modifying the modeling approach presented in section 3.3 to 
account for APEO as a target compound.    Equation (8) is the modified equation.   
                     
           
                            
                            
   3-8 
The OH∙ scavenging rate constant of different water matrices, the OH∙ formation 
rate within different AOPs, and the kinetic rate constants listed in Tables 3-2 and 3-3 
were used in Equation (8) to predict the concentration of APEO in reactor solutions after 
ten minutes.  Table 3-4 presents the predicted and observed APEO concentration.    
Table 3-3 Kinetic rate constants utilized in the presented modeling approach 
 Constant Units Reference 
         5.30E+09 M
-1
s
-1
 [107] 
        4.14E+09 M
-1
s
-1
 This Study 
         1.07E+10 M
-1
s
-1
 This study 
         1.12E+10 M
-1
s
-1
 This Study 
          1.10E+07 M
-1
s
-1
 [107] 
         2.70E+07 M
-1
s
-1
 [107] 
          6.00E+08 M
-1
s
-1
 [107] 
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Table 3-4 Final concentration of predicted and observed values of APEOs in ultrapure 
water, tap water, WWTP effluent, WWTP influent and hospital effluent for each AOP 
AOP Aqueous Matrix [OPEO]t [NPEO]t 
  observed predicted observed predicted 
  g/L g/L g/L g/L 
UH Ultrapure Water 22.3 0.66 433 112 
UH Ultrapure Water 32.5 0.66 77.4 4.76 
UH Ultrapure Water 930 279 142 23.13 
UH Ultrapure Water 168 13.5 23.5 1.34 
UH Tap Water 678 433 353 188 
UH Wastewater Effluent 1350 1240 504 565 
UH Wastewater Influent 2450 2390 1220 1120 
UH Hospital Effluent 2530 2480 1290 1160 
FH Ultrapure Water 816 91.7 473 35.2 
FH Tap Water 1050 1130 431 512 
FH Wastewater Effluent 2100 1940 964 901 
FH Wastewater Influent 2720 2620 1210 1240 
FH Hospital Effluent 2760 2660 1330 1260 
UFH Ultrapure Water 260 2.27 150 1.05 
UFH Tap Water 1130 498 481 236 
UFH Wastewater Effluent 2190 1390 870 656 
UFH Wastewater Influent 2370 2460 1000 1160 
UFH Hospital Effluent 2510 2530 1170  1200 
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Predicted and observed [APEO] concentrations are used to calculated fractional 
removal    
       
       
 .  Figure 3-4 represents the predicted versus observed fractional 
removal of APEOs and the residual plot when the data is fitted to a linear equation with 
slope equal to one and an intercept equal to zero using a linear squared method.  The 
summary of goodness of fit analysis of the model is presented in Table 3-5.   
The data presented in Figure 3-5 was further evaluated by considering two 
groups of data.  Group 1 consisted of all data with fractional removals less than 0.5 and 
Group 2 consisted of all data with fractional removals greater than 0.5 (group 2).  The 
average residuals for Group 1 data (0.06) were lower than the average residuals for 
Group 2 data (0.11).  A further exploration of the data reveals that Group 2 corresponds 
to the experiments carried out in ultrapure water, tap water and wastewater treatment 
plant effluent while Group 1 data corresponds to experiments conducted with wastewater 
treatment plant influent and hospital effluent.  These findings suggest that there is 
greater deviation within the predicted values from the experimental values for Group 2 
data points when compared with Group 1 data points.   
The observed difference can be explained due to the basic model assumption that 
the concentration of the all the scavenging species within the water matrix does not 
change with reaction progression.  However, with the ultrapure water this assumption 
cannot be true due to an overall lack of OH· scavenging species.  This explanation can 
also be extended to tap water and WWTP effluent due to low concentrations of dissolved 
organic carbon observed in those samples.  Therefore, before implementing AOPs as a 
treatment / pretreatment technology for removal of APEOs with different water matrices, 
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it is important to understand the rate of hydroxyl radical formation along with the 
scavenging capacity of water.   
Table 3-5 Goodness of fit statistics for fitted predicted fractional removal of APEOs with 
a linear polynomial with slope as one and y-intercept as zero 
Fittedmodel  
Linear model 
Poly1: 
Fittedmodel1(x)=p1*x + p2 
Coefficients (with 95% confidence bounds): 
p1 =  1 (fixed at bound) 
p2 = 0 (fixed at bound) 
SSE 0.585 
R2 0.884 
DF 36 
Adjusted R2 0.887 
RMSE 0.127 
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Figure 3-5 Plots of predicted versus observed values of fractional removal of APEO for 
all the performed experiments.  Trends in the data are observed when separating the plot 
into two respective groups.  Group 1 has predicted removals less than 50% and 
corresponds to the hospital effluent and wastewater influent samples and Group 2 has 
predicted – observed removals greater than 50% corresponding to ultrapure water, tap 
water, and wastewater effluent samples. 
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3.3.5 Implications for using AOPs to treat APEOs in wastewater 
The reaction of APEOs with OH∙ in ultrapure water and aqueous environmental 
matrices followed second-order reaction kinetics with a calculated rate constant for both 
APEOs of 1.1x10
10
 M
-1
s
-1
.  During the reaction of APEOs with OH∙, APEOs with lower 
ethoxylate chain length were formed, indicating fragmentation.  While formation of 
APEOs with smaller ethoxylate chains was observed, the concentration of all APEOs 
decreased rapidly in solution.   
Removal of APEOs was observed in all aqueous environmental matrices by all of 
the evaluated AOPs.  The differences in the percent removal of APEOs for each water 
matrix–AOP pair can be explained by the rate of OH∙ formation, which is affected by the 
oxidant used by each AOP, and by the rate of OH· scavenging, which is affected by 
concentrations of scavenging chemicals in the aqueous environmental matrix.  
Predictions of fractional removal of APEO within each matrix-AOP pair describe the 
experimental data well (r
2
 of 0.88).  The presented modeling approach can also be used 
to design an advanced oxidation process to remove APEOs from aqueous systems by 
utilizing the model to estimate the dosages of oxidant based upon the time required to 
achieve desired removal of APEOs.  Therefore, the presented approach can be used by 
municipalities and design engineers to assess the location for implementing treatment 
within a wastewater conveyance system or treatment system based on the technical and 
economic feasibility.      
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4. MOLECULAR OZONATION OF ALKYLPHENOL ETHOXYLATES IN 
AQUEOUS SYSTEMS 
4.1 Introduction 
Alkylphenol ethoxylates (APEOs) are an important class of non-ionic surfactants 
[71, 72].  Due to their widespread use in industrial processes and consumer products, 
APEOs are released to wastewater [47, 71, 72, 78-80].  Concern over the presence of 
APEOs in wastewater arises from the observation that APEOs degrade into alkylphenols 
(APs) during biological processes occurring in municipal wastewater conveyance and 
treatment systems [48, 81, 83].  The presence of APs in wastewater is problematic 
because APs are recognized endocrine disrupting compounds (EDCs) that contribute to 
the observed estrogenicity of treated wastewater effluents [30, 47, 81-84].  Therefore, 
evaluating treatment technologies that can remove APEOs, APs, and other EDCs from 
wastewater is one of the most current and important challenges facing wastewater 
engineering research.      
Recently, our research group evaluated the ability of advanced oxidation 
processes to treat APEOs present in water and wastewater (Section 3).  While APEOs 
were degraded due reaction with hydroxide radicals, low levels of shorter chain APEO 
degradation products were observed during the reaction.  While the ability to remove 
APEOs through advanced oxidation processes is evident, an interest in oxidation 
systems with the selective capability to eliminate the APEO phenolic ring without 
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forming shorter chained APEO degradation products during the reaction process is 
desirable as the phenolic ring is responsible for the ability of the compound to disrupt 
endocrine systems [38, 85, 86, 108]. 
Ozone is a well known and powerful oxidant (E
0
 = 2.08 V) commonly used in 
treatment process applications to remove organics from water and wastewater [62, 102, 
109-111]. While the treatment of organics with ozone at high solution pH (pH>9) leads 
to the formation of hydroxide radicals that dominate the oxidation mechanism, ozonation 
at neutral and acidic pH fosters the formation of molecular ozone that has demonstrated 
specificity for reacting with double bonds within aromatic rings [103, 112].  The use of 
molecular ozone has proven effective for removing micropollutants from wastewater 
[100, 101, 103, 104, 113, 114] and has been previously investigated for the oxidation of 
APs and phenols from water and wastewater [105]. However, oxidation of APEOs in the 
presence of molecular ozone has not previously been explored.  
Research was carried out to assess the ability of molecular ozone to degrade 
APEOs from aqueous matrices through selective reactivity with the phenolic portion of 
the molecule.  This chapter presents the kinetic rate constants for the reaction of 
nonylphenol ethoxylate (with an average ethoxylate chain length of 15) and octylphenol 
ethoxylate (with an average chain length of 10) with molecular ozone in batch and semi–
batch reactors.  The aims of the experiments presented in this research were to determine 
the effectiveness of molecular ozone in oxidizing APEOs; to determine the second-order 
rate constants for the reaction between molecular ozone and NPEO or OPEO; to 
understand the impact of different aqueous environmental matrices on the rate constant 
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and removal efficiency of APEOs; to understand the effect of the ethoxylate group chain 
length on the kinetic rate constant; and to determine the mechanism of molecular ozone 
reaction with APEOs.  The resulting data has important implications for using ozone as a 
treatment technology to remove APEOs from municipal or industrial wastewater.   
4.2 Experimental Section 
4.2.1 Chemicals and reagents 
Triton-X 100™ (an OPEO mixture with a mean ethoxylate chain length of 10) 
and Tergitol 15™ (a NPEO mixture with a mean chain length of 15) were purchased 
through Dow Chemical (Midland, MI, USA).  A Barnstead NANOpure water unit was 
used to produce the ultrapure water used in the oxidation experiments. Acetonitrile 
(HPLC grade), glacial acetic acid, phosphoric acid, phosphate buffer and tert-butanol 
were purchased from Fisher Scientific (Pittsburg, PA, USA). Nonylphenol (NP) and 
octylphenol (OP) were purchased from Sigma Aldrich 
20 g/L stock solutions of OPEO and NPEO were prepared by dissolving neat 
compound in ultrapure water at 40 
o
C with continuous stirring.  Stock solutions were 
stored covered at room temperature and were immediately used.  Small aliquots (spikes) 
of OPEO and NPEO were directly added to the batch or semi-batch reactor system to 
achieve the desired APEO concentration in the reactor.  For the batch reactor system, 18 
ppm ozone stock solution was prepared by dissolving ozone produced by the ozone 
generator in ultrapure water that was acidified to pH 3 using phosphoric acid.  All ozone 
stock solutions were prepared in an ice bath. [104, 115].  Ozone was generated for batch 
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and semi-batch reactor experiments using pure industrial grade oxygen connected to a 
TG-10 Ozone Solutions (Hull, IA) ozone generator.    
4.2.2 Experimental system description 
Experiments were carried out at ambient temperature (22 °C) using triplicate 2-L 
glass beakers that were continuously stirred.  The batch reactor system, used to study 
reaction kinetics and degradation product formation in ultrapure water, consisted of 1L 
of pH-buffered (pH of 3 or 6) ultrapure water with an initial ozone concentration of 0.4 
ppm.  The pH was buffered using phosphoric acid and/or phosphate buffer.  Tert-butanol 
was also added to the batch reactor at a concentration of 10 M to serve as a hydroxyl 
radical (OH˙) scavenger [104, 115] during the experiments.  The ozone concentration 
was monitored using an ozone probe and the self-degradation of ozone was monitored 
until the dissolved ozone concentration within the batch reactor reached 0.3 ppm (6.25 
M).  Once the ozone concentration reached 0.3 ppm, a spiked aliquot of OPEO or 
NPEO was then added to the batch reactor to achieve a reactor concentration of 62.5 M 
(ten times the ozone concentration) to begin the experimental run.  This amount of 
APEO was provided in excess to determine the pseudo first-order reaction constant for 
ozone consumption kinetics.  Ozone was continuously monitored and the decrease in 
ozone concentration was recorded every five seconds for the duration of the experiment 
to determine the kinetic rate constants.   
The semi-batch reactor system, used to determine reaction kinetic constants and 
to evaluate the impact of the matrix, consisted of 1L of ultrapure water or aqueous 
environmental matrix with a spiked OPEO or NPEO concentration of 20 M.  Ozone 
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was then bubbled into the system at a constant concentration and flow rate using a gas 
diffuser stone.  Ozone was continuously monitored and the ozone concentration was 
recorded every 30 seconds for the duration of the experiment.  Semi-batch experiments 
were sampled over five intervals to determine the concentration of OPEO and NPEO in 
the reactor as a function of time for both ultrapure water and the aqueous environmental 
matrices.   
4.2.3 Analytical methods 
Descriptions of many of the analytical methods used in this research appear in a 
previous publication [66].  Briefly, samples resulting from the reaction of molecular 
ozone with the two APEOs in ultrapure water or in aqueous environmental matrices 
were analyzed for the concentration of dissolved organic carbon, dissolved ozone, 
APEOs, nonylphenol (NP), and octylphenol (OP).  Samples of aqueous environmental 
matrices were collected from effluent mains from a hospital and wastewater treatment 
plant, an influent main from a wastewater treatment plant, and a buildings potable water 
tap using a peristaltic pump with teflonated tubing.  10-L samples of each aqueous 
environmental matrix were collected into polypropylene bottles, stored on ice for 
transport back to the testing laboratory, filtered through 1 m glass fiber filters, and used 
in the experiments with molecular ozone.     
4.2.4 Analysis of APEOs and APs 
Aqueous solutions from all semi-batch and batch experiments produced during 
the kinetic studies were transferred to 1-L amber glass bottles and sent to US EPA 
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Region 5‟s Central Research Laboratory (R5CRL) for NPEO and OPEO analysis.  
APEOs were extracted and analyzed following US EPA R5CRL‟s standard operating 
procedure MS006 V1, which is described in a previous publication [66].  The APEO 
method utilizes solid phase extraction to remove the analytes from the matrix, an 
Atlantis ™ MS C18 column (150 mm x 2.1 mm x 3 m) to chromatographically resolve 
the analytes on column, and a Waters 2659 liquid chromatography (LC) coupled with a 
single quadrapole ZQ mass spectrometer operated in positive electrospray ionization 
mode under atmospheric conditions.  A five point external calibration and single ion 
recording (SIR) is used to quantify the target analytes.   
NP and OP analyses were accomplished by a 25-L injection of reactor sample 
onto a 5-m, 4.6 mm x 100 mm Hypersil Green PAH column on the front end of a 
Thermo Surveyor LC equipped with a diode-array detector.  The two compounds were 
separated on column using a 70:30 acetonitrile:0.2% acetic acid in water isocratic eluent 
system at a flow rate of 1 mL/min.  NP and OP were detected at a wavelength of 224 nm 
and quantified using a five point external calibration curve.  
4.2.5 Degradation product identification 
Degradation products were qualitatively identified using a Finnegan LCQ Deca 
XP Max Ion Trap system operated in positive electrospray ionization mode under 
atmospheric pressure.  Analytes were introduced on column with a 25-L full loop 
injection and were separated on a 5-m, 4.6 mm x 100 mm Hypersil Green PAH 
column.  A 70:30 acetonitrile:0.2% acetic acid in water isocratic eluent system with a 0.5 
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mL/min flowrate was used to chromatographically resolve the analytes. The MS
n
 system 
was tuned on the parent compound (OPEO or NPEO) and operated using full scan mode 
with an m/z range from 250 to 800. 
4.2.6 Total organic carbon and dissolved ozone 
Standard Method 5310B was followed to determine the dissolved organic carbon 
concentration within samples on a Shimadzu 6000V TOC Analyzer [98]. Dissolved 
ozone was monitored by an online analyzer using a Q45H Dissolved Ozone Monitor.  
The monitor was calibrated by measuring dissolved ozone following Standard Method 
4500 (ozone - indigo method) [98, 115].   
 
4.3 Results and Discussion 
4.3.1 Kinetics of molecular ozone consumption 
Ozone consumption in the presence of excess APEOs was monitored at pH 3 and 
6 utilizing the batch reactor system.  Figure 4-1 presents the consumption of ozone over 
time within the batch reactor system during oxidation of OPEO and NPEO.  Pseudo 
first-order rate constants for molecular ozone consumption (k‟O3) in the presence of 
NPEO and OPEO were estimated to be 0.056 and 0.038 s
-1
, respectively and the kinetic 
rate constants were not dependent upon pH under acidic conditions.   
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Figure 4-1 Ozone consumption during the reaction of molecular ozone with NPEO and 
OPEO in ultrapure water within a batch reactor system 
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Ozone self degradation was also monitored for three minutes prior to spiking 
APEOs into the reactor to start the experimental run.  The rate of ozone self degradation 
increased from 3.0x10
-4
 to 6.0x10
-4
 s
-1
 in ultrapure water with an increase in pH from 3 
to 6. The solution pH was kept below 6 and a scavenger was added to limit hydroxyl 
radical formation so molecular ozone could be studied in isolation.  However, the self 
degradation rate of ozone within the reactor was negligible (2 orders of magnitude 
lower) compared to the ozone uptake associated with oxidation of APEOs at both pH 
levels.  Providing APEO in excess within the batch system also limited the reaction 
between ozone and APEO degradation products.     
The second-order rate constant for ozone consumption (kO3) was estimated based 
on the initial concentration of NPEO or OPEO in solution and the pseudo first-order rate 
using the following equation (1): 
       
               4-1 
The overall second-order rate constant for ozone consumption was 6.0x10
2
 and 
9.0x10
2
  M
-1
s
-1
 for OPEO and NPEO.  There is limited literature available regarding the 
second-order rate constant of ozonation of ethoxylates.  Bader and Hoigné (1981) 
reported values for ozone consumption during the oxidation of phenol as 1.3x10
3
 M
-1
s
-1
.  
Based upon our experimental data, the presence of the ethoxylate group reduces the 
second-order rate constant less than an order of magnitude.     
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4.3.2 Kinetics of APEO oxidation with molecular ozone  
Ozonation experiments were performed in a semi-batch reactor to determine the 
second-order rate constant for the oxidation of APEOs (kAPEO) by measuring the loss of 
APEO in solution.  Within the semi-batch experimental setup, the overall reaction is 
controlled by both the transfer of ozone from the gas phase to the liquid phase (mass 
transfer limited) and the reaction between ozone and the organic compounds in the water 
(chemical reaction limited).  As a result the overall rate of reaction can be limited by 
chemical kinetics, mass transfer, or a combination of both factors.   
The semi-batch reactor was operated under kinetically limited conditions for 
each experiment (observed as a buildup of dissolved ozone in solution).  The second-
order rate constant was calculated for total NPEO and OPEO by plotting 
ln([APEO]/[APEO]o) as a function of ozone exposure ( 3
0
[O ]dt
t
 ).  The overall rate 
constant obtained from the slope is independent of analyte initial concentration, ozone 
concentration, and time of the reaction as has been described by equation (2):   
   
      
       
               
 
 
     4-2 
The overall second-order rate constant for OPEO and NPEO (kAPEO) was 
determined as 1.3 x 10
2
 and 3.06 x 10
2
 M
-1
s
-1
, respectively (regression coefficient (r
2
) 
above 0.95 for both APEOs).  Ning et al. (2007) [105] previously reported second-order 
rate constants as 4.3x10
4
 and 3.9x10
4
 M
-1
s
-1 
for octylphenol and nonylphenol, 
respectively.  A comparison of the second-order rate constants for APEOs and APs 
indicates that the presence of the ethoxylate groups reduces the resulting rate constant by 
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up to two orders of magnitude.  Therefore, a higher ozone exposure is required to 
eliminate APEOs compared to APs.      
4.3.3 Determination of the stoichiometric factor 
The two rate constants, kO3 and kAPEO, are based on two different types of 
measurements.      is calculated by measuring the consumption of ozone in the 
presence of excess APEO, a pseudo first-order reaction, while       is obtained from 
measuring the consumption of APEOs in the presence of molecular ozone.  The two rate 
constants are related by the stoichiometric factor according to equation (3) [104]:  
                 4-3 
Based upon this equation and the kinetic rate constants determined through 
experimentation, the stoichiometric coefficients ( ) for NPEO and OPEO were 
calculated to be 2.95 and 4.62, respectively.  These findings agree with previously 
reported stoichiometric coefficients for the reaction of molecular ozone with organics 
[104, 114].  The reaction stoichiometry (1/  ) indicates that 0.34 moles of NPEO are 
reacted per mole of ozone consumed as compared to 0.22 moles of OPEO reacted per 
mole ozone consumed. The difference in observed reaction stoichiometry likely occurs 
due to the difference in the average ethoxylate chain length (10 for OPEO and 15 for 
NPEO), the ethoxylate chain length distribution (4-12 for OPEO and 9-18 for NPEO), 
and the resulting molecular weight differences (646 for OPEO and 820 for NPEO) 
between the two APEOs.   
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4.3.4 Ozonation and product formation 
Figure 4-2 shows the decrease in concentration observed for APEO of different 
ethoxylate chain length with 1 and 15 minutes reaction.  Concentrations of APEOs of all 
ethoxylate chain lengths decreased during the course of the reaction without the 
formation of APEOs with shorter chain ethoxylates as degradation products.  However, 
during the process of monitoring for the two APs, a degradation product peak was 
observed in the LC-diode array detector system that required further investigation with 
LC/MS
n
 for identification purposes. Figure 4-3 presents the results of the LC/MS
n
 
degradation product investigation and the resulting proposed pathway of the initial 
oxidation of APEOs with molecular ozone that was observed in our research.   
The m/z difference between each individual APEO and the resulting degradation 
product observed in reaction solution was M+16 or M+32, which are qualitatively 
identified as M+OH and M+2OH.  The M+OH represents a single hydroxyl group 
addition to the phenolic ring (a catechol derivative) and was observed for all chain 
lengths of OPEO and chain lengths of NPEO up to 12 ethoxylate units after 15 minutes 
of reaction with molecular ozone.  For NPEOs with greater than 12 units, the M+2OH 
degradation product was observed; representing a two hydroxide addition the phenol 
ring.  While the M+OH degradation product formation is consistent with previously 
reported literature for the reaction of molecular ozone with APs [105], the M+2OH 
degradation product of AP or phenol does not appear in the literature to the best of our 
knowledge.   
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Figure 4-2 Concentrations of individual ethoxylate chains lengths observed after 1 min 
and 15 min during the reaction of NPEO and OPEO with molecular ozone.  Formation 
of shorter chain APEOs or APs were not observed during the reaction with molecular 
ozone, however other degradation products are formed.
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Figure 4-3 Proposed initial reaction pathway during the oxidation of APEOs with molecular ozone 
73 
 
 
While analytical standards of the products were not available for quantitative 
analysis for mass balance purposes, the rise of the hydroxylated APEO product peak 
corresponded to a proportional decrease in APEO observed after 1 minute, 15 minutes, 
and 30 minutes of reaction.   
However, while proportionality was observed, this approach only arrives at a 
qualitative measure of the transformation of APEO to the hydroxylated APEO 
degradation product and quantitative analysis of the degradation products is required 
before a mass balance could be attempted.   
4.3.5 Impact of matrix on the effective kinetic rate constant (kAPEO, effective) 
The effect of different aqueous environmental matrices on the kinetics of the 
reaction of APEOs with molecular ozone was studied using the semi-batch reactor 
system.  kAPEOeffective was calculated based upon the removal of NPEO and OPEO in tap 
water, wastewater treatment plant effluent, wastewater treatment plant influent, and 
hospital wastewater effluent.  Table 4-1 presents the kAPEOeffective for each aqueous 
matrix.   
The observed value of kAPEOeffective determined in each aqueous environmental 
matrix trends with the amount of dissolved organic carbon (DOC) in the samples.  
kAPEOeffective decreased from tap water > WWTP effluent > WWTP influent > hospital 
effluent and the relationship between kAPEOeffective was observed to be negatively 
correlated with DOC based upon a pearson‟s product moment correlation analysis.  
However, additional samples need to be assessed to determine if this relationship is 
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statistically significant at a greater than 75% confidence level as observed with our 
experimental data.      
Table 4-1 Second-order rate constants for the reaction of APEO with molecular ozone in 
different aqueous matrices.  Except for in ultrapure water, the presented second-order 
reaction rate constant is an effective rate constant 
 
  
Aqueous Matrix 
Initial DOC 
Second-Order Rate Constant 
NPEO OPEO 
(mg C L
-1
) (M
-1
s
-1
) (M
-1
s
-1
) 
Ultrapure Water 0.00 1.54E+03 3.89E+02 
Tap Water 1.07 3.84E+02 1.90E+02 
WWTP Effluent 3.16 0.60E+02 0.10E+02 
WWTP Influent 13.25 0.23E+02 0.06E+02 
Hospital Effluent 33.94 0.10E+02 0.03E+02 
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The observed trend follows previously literature reports demonstrating the 
reduction in reaction rate constants for other trace organics in the presence of DOC [20, 
96, 104, 107].  As a consequence, ozonation of water and wastewater with higher 
organic loadings will result in slower trace organic removal than kinetic studies 
performed in laboratory waters unless a higher ozone exposure is administered.   
4.3.6 Impact of ozonation as a potential pretreatment process 
The primary concern of APEOs in wastewater is that they can degrade into APs 
due to biodegradation processes occurring in municipal wastewater conveyance and 
treatment systems [48, 81, 83].  APs are known to bind to the estrogen receptor in 
exposed organisms and are recognized as endocrine disrupting compounds.  A 
pretreatment technology that can remove APEOs before their relase from a source can 
therefore eliminate the potential estrogenicity of the water or wastewater due to the 
degradation of APEOs to APs.   At first glance, molecular ozone does appear to remove 
NPEO and OPEO from the aqueous matrices.  However, the formation of hydroxylated 
NPEO and OPEO degradation products may not actually prevent the biodegradation of 
APEOs into APs over time.  The degradation products also may have EDC effects 
greater than their precursor.       
Progressive fragmentation of the polyethoxylated side chain by hydrogen 
abstraction followed by depolymerization is suggested in the literature [116], however 
progressive fragmentation was not observed in the presence of molecular ozone within 
this study.  The observed formation of hydroxylated APEO products in our experiments 
is due to ozone‟s specificity for double bonds within the aromatic ring [103, 112].   
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Opening of the ring during ozonation of phenol and APs is also suggested in the 
literature [105, 117].  While ring breakage through product screening analysis was not 
evident based upon our analytical methods used for identification of transformation 
products, ring breakage would be preferable because the phenolic ring is responsible for 
the observed estrogenicity of APs [38, 85, 86, 108]. Based upon the experimental data 
produced during this research, the slow reaction rates and formation of structurally 
similar degradation products during the reaction suggest that molecular ozone by itself 
would not be a suitable pretreatment process for NPEOs and OPEOs.  Ozonation carried 
out at a higher pH or incorporated into an advanced oxidation system, such as 
ozone/hydrogen peroxide, should lead to faster reaction kinetics without the observed 
formation of hydroxylated APEO degradation products due to reactions with the 
hydroxide radical.  Use of ozone in a way that promotes formation of the hydroxyl 
radical is a more preferable approach for pretreatment of APEO in aqueous systems. 
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5. CONCLUSION  
The aim of this dissertation was to perform research needed for risk management 
of PPCPs in healthcare facility wastewaters.  The two broad hypotheses investigated to 
achieve this aim.  Hypothesis 1 was “Healthcare facilities are a source of PPCPs to 
municipal wastewaters” and Hypothesis 2 was “Chemical oxidation processes can be 
used to remove APEOs from water and wastewater”.  Screening-level analytical studies 
were carried out on effluents from four healthcare facilities to determine the composition 
and magnitude of 94 individual PPCP analytes present in the wastewater leaving each 
facility in order to evaluate Hypothesis 1.   
Based upon the results of the source characterization study, APEOs were selected 
as the test chemicals to evaluate chemical oxidation options that could be used in 
pretreatment systems for healthcare facility or industrial process waters.  Three advanced 
oxidation processes (UV – hydrogen peroxide, Fenton‟s process, and photo Fenton‟s 
process) and molecular ozone were investigated to elucidate the OH∙ and molecular 
ozone reaction kinetics with APEOs, to investigate degradation products formed during 
the oxidation process, and to explore impacts of different aqueous matrices on reaction 
kinetics.   
The primary findings of research directed toward evaluating Hypothesis 1 
include: 1) PPCPs are present and identifiable in healthcare facility effluents, 2) each 
sampled facility wastewater exhibited different PPCP concentrations and mass loadings 
based upon the type of medical services provided within the facility and the health of the 
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patients; 3) of the 94 individual analytes measured in this research APEOs were the 
dominant PPCP class accounting for more than 65% of the total mass loading observed 
leaving three of the four facilities; and 4) healthcare facilities are a source of PPCPs to 
the environment, but their contribution to the magnitude of PPCPs in municipal 
wastewater and the surrounding environment will be determined by the location of the 
healthcare facility within a wastewater conveyance system and the flow of wastewater 
released from the facility.   
Seventy-one out of the 94 measured pharmaceutical analytes were detected in 
wastewater from at least one facility during the research and the concentrations ranged 
from below 1 nanogram per liter to hundreds of micrograms per liter.  The differences in 
pharmaceutical composition observed in the healthcare effluents and the mass loadings 
of total pharmaceuticals are shown in Figure 5-1.  It is interesting to point out that 12 of 
the pharmaceuticals were observed in at least one facility‟s wastewater at concentrations 
greater than 1 g/L.  In comparison, every APEO detected in facility wastewater was 
present at concentrations above 1 g/L with a maximum observed NPEO concentration 
of 260 g/L in the assisted living facility wastewater.  Because APEOs were present at 
high concentrations when detected, APEOs in three of the four sampled facilities 
dominated the overall PPCP composition as shown in Figures 5-2.  Only the nursing 
home wastewater was not dominated by APEOs and this is likely because the linens at 
the faculty were laundered off-site (although we never did confirm this plausible 
explanation).   
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While the source characterization data provided by this study clearly shows the 
presence of PPCPs in healthcare effluents, the overall importance of healthcare facility 
PPCP release compared to other sources within a municipal wastewater system is 
difficult to establish.  Assessing the PPCP inter-facility variability and temporal 
variability needs to occur as part of future work to determine the importance of 
healthcare facilities as PPCP sources to municipal wastewaters.       
 
 
Figure 5-1 Composition of pharmaceuticals present in each facility wastewater along 
with the estimated mass loading of total pharamceuticals leaving each facility through 
effluent discharges to the municipal wastewater system  
Flow rate  
~ 500,000 
L/day 
The letter corresponds to ATC code for pharmaceuticals 
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Figure 5-2 Contribution of pharmaceuticals, APEOs, and hormones to estimated total 
PPCP daily mass loading from each facility type 
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Additionally, knowledge of the wastewater flows within a given municipal 
wastewater system is also essential to assessing the overall importance of any facility to 
PPCP loadings to the municipal wastewater conveyance systems.  In the sampled 
municipality, the four healthcare facilities that were sampled contributed only 0.2% of 
the total wastewater flow treated by the municipal treatment plant.  In the case of this 
municipality, the municipal wastewater flow will dilute out the signal from each facility.  
However, one can easily envision situations where a large healthcare facility could 
dominate wastewater flow in small municipal systems.  Where these situations arise, risk 
management approaches should be considered.  Impacted municipal treatment facilities 
could rely on source reduction approaches and on onsite pretreatment to reduce the 
loading of PPCPs passed to the municipality‟s treatment facilities instead of upgrading 
its capabilities.     
Research directed toward evaluating Hypothesis 2 provides an initial dataset that 
adds to the discussions concerning pretreatment as a risk management approach for 
PPCPs that are currently occurring within EPA as a result of our source characterization 
work.  An evaluation of chemical oxidation processes with a focus on their potential 
implementation as pretreatment technologies (or even potentially as a tertiary treatment 
approach at wastewater plants) was explored.  APEOs were selected as test chemicals 
because of 1) their abundance in the sampled healthcare facility wastewaters; 2) the fact 
that APEOs degrade to APs during wastewater conveyance and treatment (which leads 
to endocrine active degradation products); and 3) the absence of experimental data in the 
literature on the treatment of APEOs by chemical oxidation processes.   
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As part of this research, chemical oxidation systems were screened and evaluated 
as potential pretreatment technologies to remove APEO from water and wastewater.  
The two main oxidative technologies explored used ozone and hydroxyl radicals as 
oxidants.  The hydroxyl radicals were produced by AOPs that used hydrogen peroxide.  
Hydrogen peroxide and ozone are easy to implement in pretreatment systems, either as 
part of a continuous flow through reactor system.  The UV-H2O2 AOP was the primary 
focus of research in order to gain information on the AOP process that appears most 
feasible for implementation as a pretreatment technology.  Therefore, the UV-H2O2 
system was used to understand the reaction kinetics and degradation product formation 
during the reaction of APEOs with OH∙ in ultrapure water.  Fenton‟s and photo Fenton‟s 
were then explored due to interests in generating basic scientific data missing from the 
literature.  Also, to evaluate if Fenton‟s would have a higher rate of reaction than UV-
H2O2 system and if secondary reactions would occur with iron as it is present in the 
conveyance system or wastewater if UV-H2O2 was employed in practice.   
Because the investigated AOPs produce OH∙ , which is responsible for the non-
selective oxidation of target organics, we were also interested in learning about the 
performance of a selective oxidant that could be used to particularly degrade the 
phenolic ring within APEO.  The phenolic ring is responsible for the estrogenic activity 
of the molecule and breaking the ring would be a successful approach to removing the 
environmental concern of APEO in wastewaters.  Molecular ozone was selected based 
upon its selectivity for reactions with aromatics and due to previous suggestions in the 
literature that pointed towards ring cleavage when molecular ozone reacted with phenol 
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and APs.  Laboratory experiments focused on the reactivity of molecular ozone with 
APEOs, because ozone also leads to the formation of OH∙ at higher pH ranges and the 
reactivity of OH∙ with APEO had been explored through investigation of the UV-H2O2 
system.  By controlling the solution pH and adding OH∙ scavengers, the molecular 
reactivity of ozone could be studied in isolation. 
Important findings from the oxidation studies include 1) both AOPs and 
molecular ozone were able to remove APEO from aqueous environmental matrices, 2) 
understanding degradation product formation is critical to selecting a suitable treatment 
process, 3) using AOPs at a wastewater source will require higher oxidant loadings to 
overcome competition of DOC with the oxidant, 4) UV-H2O2 and ozone (particularly a 
ozone-H2O2 system) have application as a pretreatment technology for PPCPs in 
healthcare facilities, and 5) UV-H2O2 could be implemented at the full plant scale to 
achieve removal of PPCPs from effluents. 
Both the evaluated AOPs and molecular ozone removed APEO from ultrapure 
water and actual environmental samples.  However, the second-order kinetic rate 
constant for OH∙ reaction with APEO was 7 to 8 orders of magnitude higher than the 
second-order rate constant for the reaction of molecular ozone with APEO.  
Additionally, while no difference was observed between NPEO and OPEO reactivity 
towards OH∙, there was an observed difference in the reactivity of NPEO and OPEO 
with molecular ozone; hinting at the difference in reaction mechanism between OH∙-
APEO and molecular ozone-APEO.   
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For OH∙ reaction, the resulting ethoxylate chain length profile during the reaction 
showed the formation of shorter ethoxylate chain length APEOs not present in the 
original spiked mixture indicating fragmentation of the ethoxylate moiety.  However, 
OH∙ reaction with APEOs rapidly decreased the overall APEO concentration and the 
amount of shorter chain APEOs formed during the reaction also were reduced as a 
function of reaction time.  For molecular ozone‟s reaction with APEO, the ethoxylate 
chain length profile during the course of reaction with ozone did not change with time 
(fragmentation of APEO chain lengths was not observed).   However, the reaction of 
molecular ozone with APEO produced hydroxylated APEOs as a predominant 
degradation product.  While the amount of hydroxylated APEOs was not able to be 
quantified due to lack of appropriate analytical standards, the rise of the degradation 
products appeared proportional to the decrease of APEO in solution.  Therefore, 
molecular ozone is not likely to be a useful pretreatment technology for APEOs as 
APEOs are transformed but not completely removed.        
The effect of real aqueous environmental matrices on the removal of APEOs is 
similar whether OH∙ or molecular ozone is used.  Dissolved organic carbon was the 
major factor contributing towards the decline in fractional removal of APEOs.  
Therefore, aqueous environmental matrices with higher DOC content will have lower 
fractional APEO removal when the same oxidant loading rates are utilized.  For OH∙ 
reactions, the OH∙ formation rate by an AOP and the OH∙ scavenging rate constant by a 
given matrix can be used to design a treatment process to achieve a given removal of 
APEO by using the modeling approach presented in Section 4.  This approach will prove 
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useful if AOPs are implemented as treatment technologies for PPCPs in wastewater 
either at a source (in the effluent line of a hospital for instance) or as a last polishing step 
for municipal wastewater effluents (introducing H2O2 right before existing UV 
disinfection systems would be an easy addition).  
Collectively, our research carried out to evaluate Hypothesis 2 informs risk 
management decisions concerning the use of oxidation systems as treatment 
technologies for PPCPs.  However, whether or not to treat and where to treat are 
additional questions worth discussing.  Based upon our research, deciding whether or 
not to treat is not determined by available technologies, but rather social political factors 
that are currently driven by economics and public interest.  Justifying an extensive 
change of infrastructure to remove PPCPs from municipal wastewater is not feasible.  
However, if small adaptations can be made or source pretreatment could be brought on-
line at low cost, we conclude why not treat?  While pollution prevention measures are 
required for industrial producers of PPCPs, large facilities using and releasing high 
amounts of PPCPs to municipal wastewater should also be required to treat their 
wastewaters or to pay for upgrades of the municipal treatment plant that receives their 
wastewater discharge.  
If pollution prevention measures point towards treatment, the question becomes 
where to treat?  The location of the treatment technology will impact both the efficiency 
of any proposed technology and the cost of implementation.  Treated wastewater 
effluents have lower DOC content compared to healthcare facility effluents, so treatment 
process efficiency may make up for the difference in cost caused by the scale of 
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treatment required between an individual facility and the total wastewater flow in a 
given municipal system.  Additionally, many wastewater treatment plants are now 
equipped with UV reactors for disinfection purposes and adding H2O2 may not 
significantly enhance capital or infrastructure costs.  In the end, economic feasibility will 
actually drive the decision on where to implement the removal technology.  Performing 
such an economic feasibility assessment would be a nice addition to our knowledge base 
that could be accomplished using the data presented in this dissertation.  Additionally, it 
is hoped that this research will be used by municipal utility manager, regulators, and 
facility managers to determine if risk management approaches to reduce PPCPs in 
healthcare facility wastewaters within their jurisdiction should occur.  
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